Publication | Open Access
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
591
Citations
17
References
2018
Year
ClinicalTrials.gov identifier: NCT02388919.
| Year | Citations | |
|---|---|---|
Page 1
Page 1